Efficacy Data on Combination ADT/Apalutamide from the TITAN Trial and Real-World Analyses


A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.

Patient Profile: A 60-Year-Old-Man with Prostate Cancer

Initial Presentation (Jan 2019)

A 60-year-old man presented with urinary retention, fatigue, and decreased appetite

No family history of prostate cancer

Clinical workup

PSA 15 ng/mL; Hb 9.7 g/dL; ANC 1.9

DRE suggested mild abnormality/firmness with potential prostate cancer

Transrectal ultrasound (TRUS)-guided biopsy of the prostate confirmed Grade Group 2/stage c2b adenocarcinoma of the prostate, with 10 of 12 positive cores

MRI was negative for LN involvement


Initial Treatment (Feb-April 2019)

Patient underwent radical prostatectomy with pelvic lymph node dissection; specimen analysis revealed margin-negative, stage pT3b, node-negative, Grade Group 2/stage IIB adenocarcinoma of the prostate

Patient achieved nadir PSA within 3 months of surgery, but PSA subsequently rose to 0.5 ng/mL

Patient then underwent salvage EBRT (2.7 Gy x 26 fractions)

Post-EBRT PSA level was undetectable

6- and 7-month Post-Treatment Followup Notes (October-November 2019)

Patient’s PSA levels increased to 27.3 ng/mL in 10/2019 and 61.7 ng/mL in 11/2019.

MRI revealed two visceral metastases, one in the left lobe of the liver and one in the left superior lobe of the lung.

Given the recent findings, the patient and clinician discussed next steps for treatment. The patient noted that he still has a full-time job and enjoys being active with his family. He expressed concern about potential side effects of systemic therapy interfering with these aspects of his life.

They ultimately decided to initiate combination therapy with leuprolide and apalutamide.

Related Videos
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Paul E. Dato, MD, an expert on prostate cancer
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Charles Parker, MD, answers a question during a Zoom video interview
© 2023 MJH Life Sciences

All rights reserved.